Internal Medicine, Infectious Disease · Miami, FL
NPI
1912964156
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
8260 W Flagler St Ste 2h
Miami, FL, 33144
Phone (305) 229-0551
Groups this clinician bills Medicare through
Medicare paid, 2024
$55K
669 services
Medicare patients, 2024
272
Average age 83
Drug cost, 2024
$2.9M
1,740 prescriptions
Company payments, 2025
$43.98
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Luis A Miller was code 99232 (hospital e&m - subsequent), 309 times for 133 patients. In total Luis A Miller billed 669 services in 9 codes, and Medicare paid $55K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-09-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 309 | 133 | $63.47 | $20K |
| 99222 Hospital E&M - Initial | Facility | 182 | 157 | $100.33 | $18K |
| 99233 Hospital E&M - Subsequent | Facility | 142 | 72 | $98.03 | $14K |
By year: 2022 $73K for 1,062 services; 2023 $86K for 945 services; 2024 $55K for 669 services.
Medicare prescription drug claims, 2024
In 2024, the drug Luis A Miller prescribed most often to Medicare patients was Genvoya (Elviteg/Cob/Emtri/Tenof Alafen), with 275 prescriptions and refills. In total Luis A Miller wrote 1,740 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 275 | 275 | 32 | $1.2M |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 135 | 138 | 16 | $586K |
| Descovy Emtricitabine/Tenofov Alafenam | 100 | 102 | Under 11 | $242K |
| Mupirocin Generic | 87 | 87 | 49 | $207 |
| Tivicay Dolutegravir Sodium | 74 | 74 | Under 11 | $179K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 72 | 78 | 40 | $161 |
| Linezolid Generic | 68 | 68 | 42 | $2,000 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 49 | 49 | Under 11 | $197K |
| Levofloxacin Generic | 48 | 51 | 46 | $212 |
| Juluca Dolutegravir/Rilpivirine | 42 | 42 | Under 11 | $158K |
| Efavirenz-Emtric-Tenofov Disop Efavirenz/Emtricit/Tenofovr Df | 41 | 41 | Under 11 | $1,942 |
| Estradiol Generic | 40 | 114 | 28 | $577 |
| Fosfomycin Tromethamine Generic | 39 | 39 | 32 | $3,790 |
| Ciprofloxacin Hcl Generic | 38 | 39 | 27 | $132 |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | 36 | 36 | 22 | $225 |
Brand drugs: 816 claims; generic drugs: 924 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Luis A Miller $43.98 ($43.98 in general payments such as food, travel and fees) from 1 company. The largest payer was Janssen Biotech, Inc. with $43.98.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 2 | $43.98 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.